While the efficacy of CD19-CAR T cells is well-documented [1, 4–8], data on B-cell Maturation Antigen (BCMA)-CAR T cells in multiple myeloma (MM) are still emerging. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.